NASDAQ:GHRS GH Research Q1 2026 Earnings Report $21.16 -0.11 (-0.49%) As of 11:42 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast GH Research EPS ResultsActual EPSN/AConsensus EPS -$0.27Beat/MissN/AOne Year Ago EPSN/AGH Research Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGH Research Announcement DetailsQuarterQ1 2026Date5/14/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile GH Research Earnings HeadlinesGH Research (GHRS) Expected to Announce Quarterly Earnings on ThursdayMay 6, 2026 | americanbankingnews.comGH Research Raises $111 Million in Completed Share Offering to Fund Depression PipelineApril 30, 2026 | tipranks.comNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Central banks bought a record 863 tonnes in 2025 alone - and one small-cap explorer in Nevada's Walker Lane Belt may be positioned to benefit. Sitting 18 miles north of Tonopah in the same district that produced over 15 million ounces at Kinross Gold's Round Mountain Mine, this explorer carries historic drill intercepts of 30 meters at 2.5 g/t gold and surface samples exceeding 100 g/t. With a market cap under $15 million and drills ready to turn in H2 2026, the window may be narrow.May 12 at 1:00 AM | Wall Street Logic (Ad)GH Research Announces Pricing of $117.5 Million Underwritten OfferingApril 29, 2026 | globenewswire.comGH Research: WH Decision On Psychedelics To Treat Depression Makes Bull CaseApril 20, 2026 | seekingalpha.comGH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental IllnessApril 20, 2026 | globenewswire.comSee More GH Research Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email. Email Address About GH ResearchGH Research (NASDAQ:GHRS) Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health. The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression. An additional preclinical candidate, GH002, is being developed for broader indications including anxiety, cognitive impairment and substance use disorders. GH Research employs a proprietary platform to optimize dosing, formulation delivery and real-time patient monitoring. Founded in 2017 by biotechnology entrepreneur Christian Angermayer, GH Research operates research facilities in Ireland and maintains collaborations with academic institutions and contract research organizations across Europe and North America. The executive leadership team combines expertise in psychiatry, neuroscience and drug development to advance the company’s pipeline. GH Research engages with regulatory authorities in multiple jurisdictions as it plans to initiate later-stage clinical trials and pursue strategic partnerships. The company’s goal is to bring innovative, psychedelic-derived therapeutics to patients worldwide who face debilitating psychiatric conditions.View GH Research ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles On Holdings Sets Up for Marathon Rally: New Highs Are ComingMP Materials Is Quietly Building a Rare Earth PowerhouseUbiquiti’s Uptrend Can Continue, But Don’t Rush to Buy ItAI Demand Fuels Strong Q1 Earnings for Constellation EnergyMercadoLibre Boldly Invests in Growth: Discount DeepensManic Monday.com: The Rally Is Just the Beginning for this SaaS LeaderMeta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now Upcoming Earnings Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026)Applied Materials (5/14/2026)Brookfield (5/14/2026)National Grid Transco (5/14/2026)NU (5/14/2026)Mizuho Financial Group (5/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
